Compare · NVO vs SLRN
NVO vs SLRN
Side-by-side comparison of Novo Nordisk A/S (NVO) and ACELYRIN INC. (SLRN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SLRN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $191.82B.
- NVO has hit the wire 8 times in the past 4 weeks while SLRN has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 10 for SLRN).
- Company
- Novo Nordisk A/S
- ACELYRIN INC.
- Price
- $41.50-3.35%
- $2.27+2.25%
- Market cap
- $191.82B
- -
- 1M return
- -9.37%
- -
- 1Y return
- -45.01%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SLRN
- Director Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.
- Chief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Cozadd Bruce C
- Chief Legal Officer Murugan Amar returned 121,587 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Seidenberg Beth C returned 9,850,729 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Mpofu Shephard returned 121,789 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Gosebruch Henry O returned 50,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Machado Patrick returned 14,675 shares to the company (SEC Form 4)
- Director Svoronos Dawn returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)